Immunotherapy for Advanced Melanoma: 5-Year Survival Data
Five-year overall survival reached 52% with combination immunotherapy vs 34% with monotherapy. Durable responses observed.
Company: Merck
Merck & Co. – Healthcare company
Laser Treatment for Recalcitrant Warts: Comparative Study
Pulsed dye laser achieved 78% complete clearance vs 41% with cryotherapy. Fewer treatments required with laser.
Systemic Therapy for Hidradenitis Suppurativa: Real-World Outcomes
Biologic therapy achieved 63% HiSCR response at 16 weeks in real-world setting. Quality of life improved significantly.
Novel Anticoagulant Shows Superior Outcomes in Atrial Fibrillation
New anticoagulant demonstrates reduced stroke risk and fewer bleeding events compared to warfarin in AF patients.